Vinay Mehindru, MD, MBA Appointed to RetinalGenix Technologies Inc. Board of Directors – Yahoo Finance
Appointment Expected to Support Initiatives to Improve Population Health Management and the Company’s Planned Listing Upgrade from OTCBQB to NASDAQ
Vinay Mehindru joins Retinalgenix Board of Directors
PETALUMA, Calif., July 26, 2022 (GLOBE NEWSWIRE) — RetinalGenix™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today the appointment of Vinay Mehindru, MD, MBA to the RetinalGenix Technologies, Inc. Board of Directors.
Dr. Mehindru is a multi-talented top-level executive with over 25 years of healthcare experience. His leadership spans population health and financial performance management. He has led multiple physician performance enhancement strategies and built stakeholder alliances with clinical and financial integration. He is currently serving on the board of directors of Sanovas, Inc., SteriView™ Technologies, Inc., Intubation Science™, Inc, SinuGeniX™, Inc., OtoGeniX™ Inc., PulmoGeniX™ Technologies, Inc., and GastroGeniX™, Inc.
Graduating from medical school at age 21, Dr. Mehindru was one of the youngest graduates in his country of birth, India. At age 27, he served on the faculty of the Cleveland Clinic where he was a top-tier internal medicine resident and did research in gastroenterology. Vinay has a second residency from the University of Florida in emergency medicine.
Vinay joined a private group of emergency physicians on the east coast of Florida with 47 providers, 75 employees, and over 100,000 annual visits. He has tremendous experience in airway management; working at a level-two trauma center for 10 years. For 16 years, he had been an instructor teaching difficult airway management for both cardiovascular life support and pediatric advanced life support.
At the University of Texas at Dallas, he received an Executive MBA with honors, earning the Beta Gamma Sigma Award offered only to the world’s top 5% of business students. Dr. Mehindru is the Founder & CEO of Exemplary Health, a fully integrated health plan for self-funded employers built on the principles of population health management. With AdventHealth he has been a Chief Medical Officer and was President of AdventHealth’s Physician Network, Tampa Bay, a population health company. As President of AdventHealth’s clinically integrated networks, Dr. Mehindru built a network of 1,000 physicians and established quality benchmarks and metrics. He successfully reduced the annual historical increase in the cost of their employee health plan. As a voting member of AdventHealth West Florida Division Strategy and Growth council, Dr. Mehindru oversaw strategic initiatives of this $1.5 billion revenue division.
Dr. Mehindru said, “I am excited to be on the board of RetinalGenix. This technology is designed to screen large populations at relatively lower costs and reduce the overall disease burden in the given population. It addresses all 3 components of the triple aim of population health management from the Institute for Healthcare Improvement (IHI): 1. Improve the health of the population 2. Reduce per capita cost 3. Improve the experience by improving the access.”
“We welcome Dr. Mehindru joining the RetinalGenix Technologies, Inc. Board of Directors. His MBA, Public health, and medical health background should complement numerous RetinalGenix initiatives including the Company’s initiatives to improve population health management and planned upgrade from OTCQB to list on NASDAQ,” said RetinalGenix’s chairman and CEO Jerry Katzman, MD.
Safe Harbor Statement
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding the appointment of Dr. Mehindru supporting the Company’s initiatives to improve population health management and planned listing upgrade from OTCBQB to NASDAQ and the Company’s technology screening large populations at relatively lower costs and reducing the overall disease burden in the given population. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the contribution of Dr. Mehindru to the Company, the ability of the Company’s technology to screen large populations at relatively lower costs and reduce the overall disease burden in the given population and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Contact:
RetinalGenix Technologies, Inc.
Jerry Katzman, CEO
jkatzman@retinalgenix.com
www.retinalgenix.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4641abf8-34d8-4897-8314-321686e36dee
Related Quotes
These companies produce the only thing that matters. Especially now.
Yahoo Finance tech editor Dan Howley breaks down Microsoft's fourth-quarter earnings results, which were a miss on both the top and bottom line.
The Russian war on Ukraine has sparked a slew of sanctions as the Western powers seek to convince Russia to desist – and counter-sanctions, as Russia seeks to push back against the West. Russia and NATO both are reluctant to shoot at each other. But Russia has a powerful sanction weapon to fall back on, to support its war policy. Germany, and much of Western Europe, imports most of its natural gas from Russia – and the Russian government is turning off that tap. Russian gas exports on the chief
Shares of Snowflake (NYSE: SNOW), CrowdStrike Holdings (NASDAQ: CRWD), and Datadog (NASDAQ: DDOG) all fell hard Tuesday, down 5.7%, 6.6%, and 5%, respectively, as of 12:30 p.m. ET. CrowdStrike did unveil a new innovation today, but it appears macroeconomic issues enhanced by a bad growth outlook from the International Monetary Fund (IMF) is overwhelming any company-specific news today. Lower growth wouldn't be good for anyone, especially growth stocks.
Dividend stocks are the Swiss army knives of the stock market. When dividend stocks go up, you make money. When they don’t go up — you still make money (from the dividend). Heck, even when a dividend stock goes down in price, it’s not all bad news, because the dividend yield (the absolute dividend amount, divided by the stock price) gets richer the more the stock falls in price. Knowing all this, wouldn’t you like to own find great dividend stocks? Of course you would! Using the TipRanks platfor
Elliott Management, the $50 billion hedge fund, has taken a stake in the payments company, The Wall Street Journal reports.
Google parent company Alphabet reported earnings that missed Wall Street expectations after the closing bell on Tuesday.
Wedgewood Partners, an investment management firm, published its second-quarter 2022 investor letter – a copy of which can be downloaded here. For the first half of 2022, a portfolio net return of -17.2% was recorded by the fund, underperforming the S&P 500 Index which delivered a -16.1% return for the same period. Go over the […]
In this article, we will look at the 7 beaten-down semiconductor stocks that Jim Cramer likes. If you want to explore similar beaten-down semiconductor stocks that are on Jim Cramer’s radar, you can also read Jim Cramer Likes These 3 Beaten-Down Semiconductor Stocks. Analysts and investors are treading carefully as they are exploring growth areas […]
The odds are good that June 16 marked the stock market’s low, and we are in the early stages of a new bull market. Inflation is rolling over. Supply chains are repairing. There is enough terror in the market to suggest we are near the bottom.
Microsoft Corp. missed expectations for profit and revenue in a Tuesday earnings report, as deteriorating economic conditions led to an even greater shock than expected when executives revised their guidance at the beginning of June.
(Bloomberg) — For analysts, the last Thursday of July is always one of the busiest dates in the calendar. This year, it’s likely to be even more of a stretch.Most Read from BloombergStar Wars Knights of the Old Republic Game Paused Amid Studio ShakeupBiden Considers New Pause on Paying Back Student Loans, $10,000 ReliefCoinbase Faces SEC Probe on Crypto Listings; Shares TumbleBiden Will Speak With Xi on Thursday as US-China Ties WorsenMagnitude-7 Earthquake Hits Philippines' Main IslandFirms in
Market watchers are widely predicting that this week’s Q2 GDP print will show a contraction – which make two quarters in a row, the definition of a recession. Consumer sentiment reports have shown that John Q. Public agrees with this assessment, and has for the last couple of months, and markets bear that out. Even after a recent rally, stocks remain down 17% year-to-date on the S&P 500 and a deeper 25% on the NASDAQ. The market turndown, however, brought plenty of stocks into discount trading t
The real estate investment platform backed by Amazon.com Inc (NASDAQ: AMZN) founder Jeff Bezos has continued ramping up its acquisitions of single-family rental homes in several U.S. markets. Arrived Homes acquires single-family homes to use as rental properties, then sells shares of these properties to investors through its online platform. The demand for rental property shares has grown exponentially so far in 2022, with more homes funded in July than the entire first quarter. The company has
As investors await another jumbo-sized rate increase from the Federal Reserve, they are taking the temperature of a weeks-long U.S. stock market rally that followed a vicious first-half selloff. Even after Tuesday's sharp fall, the S&P 500 remained up 7% from its June 16 low, buoyed in part by expectations that the Fed will pause its aggressive rate hikes early next year and a recent decline in commodity prices that investors hope will help ease inflation. "We think this is a bear market suckers' rally," said Steve Chiavarone, senior portfolio manager at Federated Hermes, who believes the Fed will remain hawkish longer than expected and has reduced his equity exposure as the S&P pushed higher over the last few weeks.
The market rally fell on a Walmart warning, with all eyes turning to the Fed meeting. Google, Microsoft led key earnings, but this stock shined.
Should we still trust the Fed? This bigwig has serious concerns.
Lately, research firms have been warning investors about softening demand in the global smartphone market.
Enphase Energy (ENPH) delivered earnings and revenue surprises of 28.92% and 4.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alphabet Inc. and Microsoft Corp. both reported results that missed Wall Street's expectations Tuesday, but not only did investors not melt down, both actually saw their stocks rise in after-hours trading.